سعر ساتوجلر 20مجم 30 قرص 2022

Satogler 20 mg film-coated tablets (atorvastatin), pack of 30, by Jedco International Co. for Pharmaceuticals, manufactured by El Razy Pharmaceuticals (Egypt); a statin lipid-lowering agent.

• Primary hypercholesterolaemia (including heterozygous familial) or combined (mixed) hyperlipidaemia, as an adjunct to diet to reduce total-C, LDL-C, apolipoprotein B and triglyceridesPopulation: Adults, adolescents and children 10 years and olderelectronic medicines compendium (emc), UK
• Homozygous familial hypercholesterolaemia, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if unavailablePopulation: Adultselectronic medicines compendium (emc), UK
• Prevention of cardiovascular events in patients at high risk of a first cardiovascular event, as an adjunct to correction of other risk factorsPopulation: Adultselectronic medicines compendium (emc), UK

• Common: nasopharyngitis, allergic reactions, hyperglycaemia, headache, pharyngolaryngeal pain, epistaxis, constipation, flatulence, dyspepsia, nausea, diarrhoea, myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain, abnormal liver function tests, increased blood CK. Rare but serious: myopathy, myositis, rhabdomyolysis, tendon rupture, cholestasis, severe skin reactions; very rare hepatic failure.International label, same formulation · electronic medicines compendium (emc), UK

• Hypersensitivity to atorvastatin or any excipient; active liver disease or unexplained persistent serum transaminase elevations exceeding 3 times ULN; pregnancy, breast-feeding and women of child-bearing potential not using appropriate contraception; concomitant glecaprevir/pibrentasvir.International label, same formulation · electronic medicines compendium (emc), UK
• Acute liver failure or decompensated cirrhosis; hypersensitivity to atorvastatin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Liver function tests before treatment and periodically thereafter; reduce the dose or withdraw if transaminases persistently exceed 3 times ULN; caution with substantial alcohol intake or a history of liver disease.International label, same formulation · electronic medicines compendium (emc), UK
• Myopathy and rarely rhabdomyolysis may occur, and very rarely immune-mediated necrotising myopathy; measure CK before treatment in patients with predisposing factors (renal impairment, hypothyroidism, personal/family history of muscle disorders, previous statin or fibrate muscle toxicity, liver disease or heavy alcohol use, age over 70); do not start if baseline CK exceeds 5 times ULN; stop if CK exceeds 10 times ULN or rhabdomyolysis is suspected.International label, same formulation · electronic medicines compendium (emc), UK
• Must not be given with systemic fusidic acid or within 7 days of stopping it (rhabdomyolysis, including fatal cases); avoid, or use lower doses with monitoring, with potent CYP3A4 or transporter inhibitors; consider suspending with daptomycin.International label, same formulation · electronic medicines compendium (emc), UK

• Potent CYP3A4 inhibitors (e.g. clarithromycin, itraconazole, HIV protease inhibitors) and ciclosporinMarkedly increase atorvastatin exposure and myopathy risk; avoid if possible, otherwise use lower starting and maximum doses with clinical monitoring (tipranavir/ritonavir or ciclosporin: do not exceed 10 mg daily).electronic medicines compendium (emc), UK
• Glecaprevir/pibrentasvirContraindicated.electronic medicines compendium (emc), UK
• Elbasvir/grazoprevir, letermovirDo not exceed atorvastatin 20 mg daily; letermovir with ciclosporin: atorvastatin not recommended.electronic medicines compendium (emc), UK

• Contraindicated in pregnancy; women of child-bearing potential should use appropriate contraception. Safety in pregnancy not established; rare reports of congenital anomalies after intrauterine exposure to HMG-CoA reductase inhibitors; animal studies showed reproductive toxicity. Treatment should be suspended for the duration of pregnancy.International label, same formulation · electronic medicines compendium (emc), UK
• Contraindicated during breast-feeding; excretion in human milk unknown, and serious adverse reactions in the infant are possible.International label, same formulation · electronic medicines compendium (emc), UK

• Atorvastatin: Inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis.